vialaudit
SEMAGLUTIDE·INDIANA·LAST CHECKED 1 NOV 2026

Is Semaglutide legal in Indiana?

CAVEATS APPLY

Since 1 Jul 2026 Indiana law (IC 16-42-22.5) bars compounding from research-grade or veterinary-grade bulk ingredients outside an IRB-approved study and requires an FDA-registered source with a certificate of analysis. From 1 Jan 2027 medical spas must register with the state medical board. Federally: Yes, as a prescription drug: FDA has approved it (Ozempic, Wegovy, Rybelsus). A vial sold as a 'research peptide' is not the approved product, and selling it for human use breaks federal drug law. Pharmacies may compound it only when the product is not a copy of the approved drug.

CATEGORY · FDA APPROVED

Full status breakdown

FEDERAL · STATE · SPORT-BODY

Federal status

FDA approval
approved as drug · brand: Ozempic, Wegovy, Rybelsus · NDA 209637 (Ozempic); NDA 213051 (Rybelsus); NDA 215256 (Wegovy) · approved Dec 5, 2017
Indications: T2DM; chronic weight management; CV risk reduction; MASH
DEA scheduling
not scheduled
503A compounding
FDA interim category: Component of an FDA-approved drug
503A Bulks List: not on list
Component of an approved drug, so a 503A pharmacy may compound it only when the result is not 'essentially a copy' of Ozempic, Wegovy or Rybelsus, and only from semaglutide base (salt forms are not the approved ingredient). Shortage-period discretion ended 22 Apr 2025 (503A) and 22 May 2025 (503B). FDA proposed on 1 May 2026 to exclude semaglutide from the 503B clinical-need list; no final notice as of 12 Oct 2026.
FDA Warning Letters
  • Feb 7, 2024 — US Chem Labs (cited: semaglutide) · LETTER ↗
  • Sep 9, 2025 — SemaBio (cited: semaglutide) · LETTER ↗
  • Sep 9, 2025 — Hims & Hers (Hers) (cited: semaglutide) · LETTER ↗
  • Feb 20, 2026 — Better Health Labs dba Measured (cited: semaglutide) · LETTER ↗
Shortage status
not currently on shortage list
Historical shortage window: Jan 1, 2022 → Feb 21, 2025
Sale framing
Research-use-only posture: RUO does not protect sellers when site evidence shows human-use intent. FDA has flagged salt-form variants of compounded semaglutide as distinct from the approved drug.
Personal possession: Not federally controlled; personal possession is not a federal crime. Approved sema is Rx-only and dispensing without prescription violates federal and state pharmacy law.

Indiana — state-specific

compounding restriction · Indiana

Since 1 Jul 2026 Indiana law (IC 16-42-22.5) bars compounding from research-grade or veterinary-grade bulk ingredients outside an IRB-approved study and requires an FDA-registered source with a certificate of analysis. From 1 Jan 2027 medical spas must register with the state medical board.

Sport-body status

WADA 2026
not prohibited
GLP-1 receptor agonists are not on the 2026 or the 2027 Prohibited List. WADA's 2027 Monitoring Program names semaglutide, which tracks use but does not ban it.
USADA
not banned
NCAA
unknown

What we couldn’t verify

Also known as

9 ALIASES

Semaglutide is also marketed or referenced under the following names (vendor pseudonyms, brand names, chemical identifiers):

  • Ozempic
  • Wegovy
  • Rybelsus
  • Sema
  • Sema-1
  • GLP-1 receptor agonist
  • NDA 209637
  • NDA 213051
  • NDA 215256

Related

FOLLOW-ONS

Semaglutide: US status, sources and what changed

Other states with a rule that names Semaglutide: California, Mississippi, Connecticut, Ohio, Alabama. Everywhere else, federal law applies.

THE ROUNDUP · MONTHLY

Receipts in your inbox. Once a month.

New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.

14,200 SUBSCRIBERS·0 SPONSORED ITEMS·11 ISSUES SINCE LAUNCH